YOD1

Across TCGA pan-cancer cohorts, YOD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated YOD1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher YOD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated YOD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where YOD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.383	0.632	.004	27	view →
CCRCC	DFS	Median	All	0.888	0.597	<.001	26	view →
LUAD	DFS	Tertile	II,III,IV	0.581	0.992	.004	19	view →
HNSC	OS	Median	All	0.911	0.795	.025	13	view →
LSCC	DFS	Median	All	0.783	0.614	.030	2	view →
GBM	OS	Quartile	All	0.865	0.732	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

YOD1–PDAC (OS)

Open the PDAC breakdown →